Datar Cancer Genetics Receives FDA Approval for CellDx-Tissue Genomic Profiling Test

Datar Cancer Genetics Receives FDA Approval for CellDx-Tissue

Datar Cancer Genetics (DCG), a global leader in precision oncology, recently announced that the U.S. Food and Drug Administration (FDA) has granted approval for its comprehensive genomic profiling assay, CellDx-Tissue. This groundbreaking test analyzes both DNA and RNA from solid tumors, enabling oncologists to make well-informed clinical decisions tailored to individual patients' genetic profiles.

Understanding CellDx-Tissue

CellDx-Tissue is an in vitro diagnostic test that employs next-generation sequencing (NGS) to analyze 517 cancer-associated genes. The assay focuses on identifying somatic nucleotide variants (SNVs), small insertions and deletions (InDels), amplifications of the ERBB2 gene, and gene fusions involving ALK, RET, and ROS1. Samples used for this analysis are derived from formalin-fixed, paraffin-embedded (FFPE) tumor tissues from patients diagnosed with solid tumors.

With the growing importance of comprehensive genomic profiling in clinical tumor management, CellDx-Tissue is positioned to significantly aid clinicians in characterizing genomic alterations across various cancer types. The FDA's approval process is notoriously rigorous, ensuring that the assay meets high standards in analytics, clinical performance, and data integrity.

Significant Impact for Oncologists and Patients

By securing FDA approval, DCG aims to enhance its partnerships with clinical, academic, and biopharmaceutical stakeholders worldwide. The approval not only complements DCG’s existing Breakthrough Device designation for liquid biopsy platforms but also underscores the company's commitment to providing actionable genomic insights.

Dr. Vineet Datta, Senior Vice President of Global Strategy and Business Development at DCG, commented, “This FDA authorization for CellDx-Tissue represents a significant regulatory milestone, bridging the gap between complex genomic data and clinical decision-making. It empowers oncologists to offer patients broader treatment options in a rapidly evolving therapeutic landscape.”

Dr. Darshana Patil, the Group's Senior Vice President of Medical Affairs, echoed these sentiments. “The FDA approval reinforces the robustness of our technology and quality systems, enabling us to supply oncologists with reliable and standardized genomic information to guide complex therapeutic decisions.”

A New Era in Cancer Precision Medicine

The achievement of FDA approval for CellDx-Tissue symbolizes a pivotal moment in transforming cancer care. With the increasing complexity of cancer therapies, it is critical that oncologists have access to accurate genomic information. The dedicated teams at DCG have meticulously ensured the consistency, rigor, and clinical relevance of the CellDx-Tissue platform, further affirming their mission to provide innovative oncology solutions.

Dr. Dadasaheb Akolkar, Director of Research and Innovation, noted, “This authorization reflects our unwavering commitment to clinical excellence, allowing us to deploy transformative precision oncology solutions to cancer patients across the globe.”

About Datar Cancer Genetics

Datar Cancer Genetics is a globally recognized precision oncology firm driven by artificial intelligence, focusing on developing advanced cancer diagnostics including non-invasive liquid biopsy options and tissue-based multi-omics solutions. With accredited laboratories in the UK, EU, and the US, the company's innovative technologies empower personalized care for patients with solid organ tumors. DCG's collaboration with clinicians and cancer centers worldwide aims to facilitate early detection, treatment selection, and monitoring of cancer cases.

For more information on CellDx-Tissue, visit Datar PGX.